<DOC>
	<DOCNO>NCT02848300</DOCNO>
	<brief_summary>This study evaluate skin pharmacokinetics tolerability bimatoprost Formulation A Formulation B follow 14 day daily topical administration male participant androgenetic alopecia ( AGA ) .</brief_summary>
	<brief_title>Local Pharmacokinetics Tolerability Bimatoprost Applied Scalp Male Patients With Androgenetic Alopecia</brief_title>
	<detailed_description>Single-center , multiple-dose study evaluting local pharmacokinetics tolerability bimatoprost follow 14 day daily topical administration bimatoprost Formulation A Formulation B ( contain 1 % bimatoprost ) scalp male patient With androgenetic alopecia</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Patients mild moderate Androgenetic Alopecia vertex area scalp . Patients uncontrolled systemic disease History significant cardiovascular disease Scarring disease , infection , abnormality scalp hair shaft systemic disease could cause temporary hair loss ( eg , seborrheic dermatitis , psoriatic dermatitis , alopecia areata , cicatricial alopecia , uncontrolled hyperthyroidism/hypothyroidism , tinea infection , genetic disorder ) Patients receive hair transplant scalp reduction Abnormal bone biomarker laboratory result .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>